Endocyte (ECYT)
Add to Watchlists Create an Alert
13.95
+0.16 +1.16%
NASDAQ
May 23, 1:49PM
BATS Real time
Currency in USD
Endocyte Revenue Quarterly:
14.51M for Dec. 31, 2012Endocyte Historical Revenue Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 14.51M |
| Dec. 31, 2012 | 14.45M |
| Sept. 30, 2012 | 12.41M |
| June 30, 2012 | 7.813M |
| March 31, 2012 | 0.00 |
| Dec. 31, 2011 | 0.191M |
| Sept. 30, 2011 | 0.00 |
| June 30, 2011 | 0.00 |
| March 31, 2011 | 0.00 |
| Dec. 31, 2010 | 0.00 |
| Sept. 30, 2010 | 0.00 |
| June 30, 2010 | 0.00 |
| March 31, 2010 | 0.00 |
| Dec. 31, 2009 | 0.00 |
| Sept. 30, 2009 | 3.00M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity. Increasing revenues over time are generally a good sign of company's growth.
While a bit obvious, if a lemonade company has sold 30 million in revenue and has 10 million in costs of goods sold, the company's revenue is still 30 million. (Expenses are not accounted in Revenue).
Learn More
ECYT Revenue Quarterly Benchmarks
| Companies | |
|---|---|
| Lannett Company | 36.56M |
| Merck | 10.67B |
| Catalyst Pharmaceutical Partners | 0.00 |
ECYT Revenue Quarterly Rankings
| Overall |
52nd percentile 3770 of 8006 |
| Sector |
58th percentile 282 of 686 in Healthcare |
| Industry |
58th percentile 28 of 68 in Drug Manufacturers - Specialty & Generic |
ECYT Revenue Quarterly Range, Past 5 Years
| Minimum | 0.00 | Dec 2009 |
| Maximum | 14.51M | Mar 2013 |
| Average | 3.492M |
